Digital health company, ResApp Health (ASX:RAP)
has signed a memorandum of understanding with global health product manufacturer, RB.
Under the MoU the companies will develop a smartphone app for consumers that utilises ResApp’s cough-based algorithms to identify different respiratory conditions and provide recommended next steps.
ResApp and RB have agreed to exclusively work together to build and test a prototype app for consumers to self-assess, or assess with the assistance of a pharmacist, their respiratory symptoms.
The clock is ticking. This exclusivity may be terminated by either party if a joint development agreement is not signed within six months.
Shares in ResApp Health (ASX:RAP)
are trading x per cent high/lower at $x.xx.